Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Analyst Update on Agilon Health: J.P. Morgan analyst Lisa C. Gill has revised estimates for Agilon Health following their fourth-quarter results, which showed an adjusted EPS loss of $(0.26) against a consensus of $(0.23), while sales met expectations at $1.52 billion. The outlook for 2025 indicates a transition year with revised revenue estimates down to $5.926 billion.
Stock Performance and ETFs: Agilon Health shares are currently down 0.48% at $4.18, and investors can gain exposure through Fidelity Disruptive Medicine ETF (FMED) and SPDR S&P Health Care Services ETF (XHS).
Analyst Views on FMED
Wall Street analysts forecast FMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 28.165
Low
Averages
High
Current: 28.165
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
